<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04016935</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-010</org_study_id>
    <nct_id>NCT04016935</nct_id>
  </id_info>
  <brief_title>EndoPredict® Extended Endocrine Trial (EXET)</brief_title>
  <official_title>EndoPredict® Extended Endocrine Trial (EXET): A Prospective Registry to Evaluate the Impact of EndoPredict® in Decisions Regarding Extended Endocrine Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Myriad Genetic Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Myriad Genetic Laboratories, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate how EndoPredict® is used clinically to inform
      treatment decisions for extended endocrine therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The EndoPredict® molecular test is validated to predict late recurrence after 5 years of
      endocrine therapy with or without treatment with adjuvant chemotherapy, and can be used to
      identify patients who can safely forego extended endocrine therapy. The purpose of this study
      is to evaluate how EndoPredict® is used clinically to inform treatment decisions for extended
      endocrine therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2, 2019</start_date>
  <completion_date type="Anticipated">September 27, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 27, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>To see what the adherence rate is to follow EndoPredict test results when making decision regarding extended endocrine therapy</measure>
    <time_frame>3 years</time_frame>
    <description>To see what the adherence rate is to follow EndoPredict test results (EPclin risk classification: Low or High) when making decision regarding extended endocrine therapy in women with ER+, human epidermal growth factor receptor 2 (HER2) breast cancer. The EndoPredict test gives a EPclin risk Score on a scale of 1 to 6. It takes into consideration the EP molecular score, tumor size and nodal status when determining the EPclin Risk Score. To determine actual treatment decisions, chart review will be performed 1 year after review of EndoPredict® test results. Comparison of actual treatment to EndoPredict® test results will indicate if treatment was consistent with test results.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To see what the adherence rate is to follow EndoPredict test results when making decision regarding extended endocrine therapy for certain criteria.</measure>
    <time_frame>3 years</time_frame>
    <description>To see what the adherence rate is to follow EndoPredict test results when making decision regarding extended endocrine therapy for the following: Nodal status, whether patients received adjuvant chemotherapy, EPclin risk classification. Also evaluate all objectives in the subset of women between 4 and &lt;5.5 years and &gt;5.5 and 7 years post diagnosis.The EndoPredict test gives a EPclin risk Score on a scale of 1 to 6. It takes into consideration the EP molecular score, tumor size and nodal status when determining the EPclin Risk Score. To determine actual treatment decisions, chart review will be performed 1 year after review of EndoPredict® test results. Comparison of actual treatment to EndoPredict® test results will indicate if treatment was consistent with test results.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To see what the adherence rate is to follow EndoPredict test results when making decision regarding extended endocrine therapy for certain clinical and pathologic criteria.</measure>
    <time_frame>3 years</time_frame>
    <description>To see what the adherence rate is to follow EndoPredict test results when making decision regarding extended endocrine therapy for the following clinical and pathologic criteria: Breast cancer type, number of positive nodes, Menopausal status at time of extended endocrine decision, Tumor grade, Ki67 status, and Adjuvant chemotherapy regimen.The EndoPredict test gives a EPclin risk Score on a scale of 1 to 6. It takes into consideration the EP molecular score, tumor size and nodal status when determining the EPclin Risk Score. To determine actual treatment decisions, chart review will be performed 1 year after review of EndoPredict® test results. Comparison of actual treatment to EndoPredict® test results will indicate if treatment was consistent with test results.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Node-positive patients</arm_group_label>
    <description>Approximately about 200 Node-positive patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Node-negative patients</arm_group_label>
    <description>Approximately about 200 Node-negative patients</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        ER+, HER2- breast cancer female patients currently on endocrine therapy at 4-7 years post
        diagnosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  At least 18 years of age at time of enrollment

          -  Able to provide informed consent

          -  ER+, HER2- breast tumor

          -  Currently receiving endocrine therapy

          -  Are between 4 and 7 years post-breast cancer diagnosis

          -  Have all available information to produce an EPclin score, including tumor stage,
             nodal status, and sufficient amount of remaining tissue or resection to perform
             genetic testing.

          -  Patient and physicians are willing to consider a change in endocrine therapy

        Exclusion Criteria:

          -  Currently active additional cancer diagnosis, except non-melanoma skin cancer

          -  Currently enrolled in an interventional clinical trial or other clinical trial that
             precludes freely making decisions regarding extended endocrine therapy

          -  More than 3 positive nodes

          -  Received neo-adjuvant treatment (new-adjuvant chemotherapy or neo-adjuvant endocrine
             therapy)

          -  Are beyond 7 years post-breast cancer diagnosis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>The primary objective of this study is to evaluate adherence to EndoPredict® test results (EPclin risk classification: Low or High) when making decisions regarding extended endocrine therapy in women with ER+, HER2- breast cancer.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joyce O'Shaunessey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>US Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diana Vogel</last_name>
    <phone>801-746-6532</phone>
    <email>dvogel@myriad.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Megan Roberts</last_name>
    <phone>801-746-6564</phone>
    <email>mastle@myriad.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Beaver</name>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-6413418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Upper St. Clair</name>
      <address>
        <city>Bethel Park</city>
        <state>Pennsylvania</state>
        <zip>15102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Butler Health System Medical Oncology</name>
      <address>
        <city>Butler</city>
        <state>Pennsylvania</state>
        <zip>16001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>steebx@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Passavant North Cranberry (OHA)</name>
      <address>
        <city>Cranberry Township</city>
        <state>Pennsylvania</state>
        <zip>16066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Erie</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Horizon</name>
      <address>
        <city>Farrell</city>
        <state>Pennsylvania</state>
        <zip>16121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufksy, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Greenville</name>
      <address>
        <city>Greenville</city>
        <state>Pennsylvania</state>
        <zip>16125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>steebx@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Indiana</name>
      <address>
        <city>Indiana</city>
        <state>Pennsylvania</state>
        <zip>15701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>steebx@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Arnold Palmer at Norwin</name>
      <address>
        <city>Irwin</city>
        <state>Pennsylvania</state>
        <zip>15642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>steebx@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Murtha</name>
      <address>
        <city>Johnstown</city>
        <state>Pennsylvania</state>
        <zip>15901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer McKeesport</name>
      <address>
        <city>McKeesport</city>
        <state>Pennsylvania</state>
        <zip>15132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ortenzio Cancer Center</name>
      <address>
        <city>Mechanicsburg</city>
        <state>Pennsylvania</state>
        <zip>17050</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
    </contact_backup>
    <investigator>
      <last_name>Adam M Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Monroeville</name>
      <address>
        <city>Monroeville</city>
        <state>Pennsylvania</state>
        <zip>15146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>steebx@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Arnold Palmer at Mt. Pleasant</name>
      <address>
        <city>Mount Pleasant</city>
        <state>Pennsylvania</state>
        <zip>15666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>steebx@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center New Castle</name>
      <address>
        <city>New Castle</city>
        <state>Pennsylvania</state>
        <zip>16105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magee-Women's Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>steebx@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (UPMC)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center St Margaret</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Passavant (HOA)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Passavant (OHA)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Northwest</name>
      <address>
        <city>Seneca</city>
        <state>Pennsylvania</state>
        <zip>16346</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Uniontown</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Washington</name>
      <address>
        <city>Washington</city>
        <state>Pennsylvania</state>
        <zip>15301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Jefferson</name>
      <address>
        <city>West Mifflin</city>
        <state>Pennsylvania</state>
        <zip>15122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>steebx@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center Williamsport</name>
      <address>
        <city>Williamsport</city>
        <state>Pennsylvania</state>
        <zip>17701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trisha Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Memorial</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trish Schneider</last_name>
      <phone>412-641-4706</phone>
      <email>defrancestn@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brenda Steele</last_name>
      <phone>412-641-3418</phone>
      <email>stbeex@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam M. Brufsky, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Blood and Cancer Care Associates</name>
      <address>
        <city>Lancaster</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dhwani Mehta</last_name>
      <email>dmehta@cbcca.net</email>
    </contact>
    <investigator>
      <last_name>Niyati Nathwani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Blood and Cancer Care Associates</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dhwani Mehta</last_name>
      <email>dmehta@cbcca.net</email>
    </contact>
    <investigator>
      <last_name>Niyati Nathwani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ER+ and HER2- Breast Cancer patients</keyword>
  <keyword>Extended Endocrine Therapy</keyword>
  <keyword>EndoPredict</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

